Eupraxia Pharma doses first patient in Phase 2b trial of EP-104GI in esophagitis

Eupraxia Pharmaceuticals (EPRX) announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis, or EoE. The Phase 2b portion of the RESOLVE study will enroll a minimum of 60 participants randomized in a 1:1:1 ratio to receive one of two doses of EP-104GI or placebo. After six months, eligible patients initially dosed with placebo may elect to receive EP-104GI. The primary objective is to assess the efficacy of EP-104GI in improving tissue health. Secondary and exploratory objectives include evaluating symptomatic improvement through patient-reported outcomes, endoscopic and histologic changes, pharmacokinetics, safety, and tolerability of the selected dose regimens. Eupraxia will report further details regarding the histological scores, symptom responses, pharmacokinetic results and safety details for cohorts 7 and 8 once data from the 12-week timepoint from cohort 8 is available, which is expected in Q3. Additional data from all cohorts from the Phase 2a open label portion will be reported over the coming months and on an ongoing basis during the conduct of the Phase 2b study. Topline data from the Phase 2b portion of the RESOLVE study is expected to be available in Q3 2026.